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OBJECTIVES: The CAPRIE study has demonstrated an
8.7% relative risk reduction (RRR) for atherothrombotic
events (vascular death, myocardial infarction, ischemic
stroke) compared with aspirin (ASA) in patients with
symptomatic atherothrombotic disease. The objective of
this study was to assess the cost-effectiveness of clopido-
grel relative to ASA for secondary prevention of ischemic
events in the Netherlands. METHODS: The cost-
effectiveness, in terms of cost per life-year saved, was
determined with a Markov model in which patients were
divided according to vascular events and time from last
event. Effectiveness data were derived from the CAPRIE
study; long-term outcomes were based on epidemiologi-
cal estimates concerning age speciﬁc event rates and case
fatality rates. Direct costs were updated from previous
studies, indirect costs were disregarded due to the age of
the patients. Discount rate was 4% for both costs and
effects. RESULTS: Compared with aspirin, using event-
speciﬁc risk reductions, 1-year treatment with clopidogrel
costs €743 more with a gain in life-years and quality
adjusted life-years (QALY’s) of 0.033 and 0.043 respec-
tively. Using a constant RRR of 8.7%, the results were
consistent providing a cost per life-year saved of €19.462
and a cost per QALY of €15.779. Sensitivity analyses
revealed that uncertainties surrounding the outcomes are
mainly driven by the expected effectiveness, most notably
when deﬁning sub-groups. The higher the risk for events,
the better the cost-effectiveness ratio. In comparison to
no treatment (ASA intolerance or previous failure) clopi-
dogrel is expected to combine gain in effectiveness (0.158
life years, 0.210 QALY’s) with savings (€332 per patient).
CONCLUSIONS: Clopidogrel is a dominant strategy in
patients not eligible for treatment with ASA. The cost
effectiveness is within an acceptable range when com-
pared with ASA, especially in high-risk patients.
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OBJECTIVES: Idiopathic dilated cardiomyopathy
(DCM) is a life threatening heart disease and major
reason for heart transplantation. Short time medical efﬁ-
cacy of immunoadsorption (IA) for DCM-patients has
been demonstrated in ﬁrst clinical studies. Objective 
of this study was to determine 5-year survival rates and
direct medical costs to calculate costs per life year gained
from a societal perspective. METHODS: Based on a pre-
viously published matched case-control study with clini-
cal endpoints 34 patients of similar age, sex, duration 
and severity of DCM were included. Inpatient hospital
costs of initial hospital stay were calculated from data
extracted from patients’ ﬁles and hospital’s internal
costing. Patients and treating cardiologists were con-
tacted, thus determining resource use for primary and
specialist’s outpatient care, inpatients hospital stays and
drugs during follow up. RESULTS: Patients treated with
IA show a highly signiﬁcant better survival: 5-year sur-
vival rate was 82% compared to 41%, Logrank statistics
after Kaplan-Meier analysis p = 0,0071. Cost for IA were
€28.400 per patient. Five-year medical costs were
€118,600 per patient of IA group and €75,500 in con-
trols; the costs per year of survival were €24,900 in IA
group respectively €28,900 in controls. Incremental costs-
effectiveness was €34,365 per life year gained. CON-
CLUSIONS: For the ﬁrst time in a matched controlled
study design survival analysis and economic evaluation of
this new emerging technology for patients with DCM
were performed. Although high initial treatment costs for
IA occur the signiﬁcantly better survival leads to reason-
able costs per LYG.
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OBJECTIVE: To investigate the use of resources and cost
implications of stroke prophylaxis with warfarin for
patients with non-valvular atrial ﬁbrillation (NVAF) 
in clinical practice. METHODS: All new patients with
NVAF referred to anticoagulation clinic over a recruit-
ment period of 21 months were studied. Patients were
interviewed personally on their ﬁrst visit then by tele-
phone call every 4–6 weeks for a mean (SD) of 19 (8.1)
months, range (10 to 31 months). They were asked about
any bleeding events or bleeding related extra doctor’s
visits, procedures or hospital admissions. We also
inquired about the method and the cost of transport to
the anticoagulation clinic, time off work for the patient
and/or his carer and the costs involved. Costs of warfarin
treatment were viewed as: a) cost of the drug; b) cost of
INR monitoring (analysis, travelling, nurse visits, time off
work, and postage); and c) and the costs associated with
bleeding (bleeding related extra-doctors visits or hospital
admissions). RESULTS: A total of 402 patients were
included. Mean (SD) age was 72.3 (10.3) years and 224
